FDA grants Breakthrough Therapy Designation for Venclexta in combination with azacitidine for the treatment of patients with myelodysplastic syndromes
Basel, 21 July 2021 - Roche (SIX: RO, ROG; OTCQX: RHHBY) today announced that Venclexta ® (venetoclax) in combination with azacitidine has been granted Breakthrough Therapy Designation (BTD) by the U.S. Food and Drug Administration (FDA) for the treatment of adult patients with previously untreated intermediate, high- and very high-risk myelodysplastic syndromes (MDS) based on the rev ised International Prognostic Scoring System (IPSS-R). MDS are a rare group of blood cancers that gradually affect the ability of the bone marrow to produce normal blood cells.2 This can lead to weakness, frequent infections, anaemia and ...
Source: Roche Media News - July 21, 2021 Category: Pharmaceuticals Source Type: news

Scientists identify protein markers related to the most common form of leukemia
(Wiley) Chronic lymphocytic leukemia (CLL) is the most common leukemia in the Western world. New research published in the Journal of Leukocyte Biology reveals that certain protein markers may indicate which patients have stable forms of CLL and which have more aggressive types. (Source: EurekAlert! - Cancer)
Source: EurekAlert! - Cancer - July 21, 2021 Category: Cancer & Oncology Source Type: news

Zydus Cadila gets tentative nod from USFDA to market cancer drug
"Ibrutinib belongs to a class of drugs known as kinase inhibitors and is used to treat certain cancers, such as mantle cell lymphoma or marginal zone lymphoma, chronic lymphocytic leukemia/small lymphocytic lymphoma, and Waldenstrom's macroglobulinemia," Zydus Cadila said. (Source: The Economic Times Healthcare and Biotech News)
Source: The Economic Times Healthcare and Biotech News - July 21, 2021 Category: Pharmaceuticals Source Type: news

Two studies by CU Cancer Center researchers explore link between inflammation and leukemia
(University of Colorado Anschutz Medical Campus) Two recent collaborative publications by CU Cancer Center members Eric Pietras, Ph.D. and James DeGregori, Ph.D., provide insights into how chronic inflammation can serve as a key factor in the development of leukemia and other blood cancers. (Source: EurekAlert! - Medicine and Health)
Source: EurekAlert! - Medicine and Health - June 28, 2021 Category: International Medicine & Public Health Source Type: news

Ibrutinib + Venetoclax Promising for Chronic Lymphocytic Leukemia
WEDNESDAY, June 23, 2021 -- Combination therapy with ibrutinib and venetoclax seems beneficial for patients with previously untreated chronic lymphocytic leukemia (CLL), according to a study published online June 10 in JAMA Oncology. Nitin Jain,... (Source: Drugs.com - Pharma News)
Source: Drugs.com - Pharma News - June 23, 2021 Category: Pharmaceuticals Source Type: news

Zanubrutinib Better Than Ibrutinib in CLL/SLL? Zanubrutinib Better Than Ibrutinib in CLL/SLL?
An interim phase 3 clinical trial analysis shows encouraging progression-free survival and lower cardiac toxicity in patients with relapsed/refractory chronic lymphocytic leukemia (CLL).Medscape Medical News (Source: Medscape Hematology-Oncology Headlines)
Source: Medscape Hematology-Oncology Headlines - June 13, 2021 Category: Cancer & Oncology Tags: Hematology-Oncology News Source Type: news

New Phase 3 Study Results Show IMBRUVICA ® (ibrutinib)-Based Combination Regimen as an All-Oral Fixed-Duration Treatment Demonstrated Superior Progression-Free Survival in Adult Patients with Previously Untreated Chronic Lymphocytic Leukemia
Raritan, N.J., June 12, 2021 – The Janssen Pharmaceutical Companies of Johnson & Johnson today announced primary results from the pivotal Phase 3 GLOW study (NCT03462719) evaluating fixed-duration IMBRUVICA® plus venetoclax (I+V) compared to chlorambucil plus obinutuzumab (Clb+O) for first-line treatment of elderly or unfit patients with chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL). The study demonstrated superior progression-free survival (PFS) of a once-daily, all-oral, fixed-duration regimen of I+V versus Clb+O as first-line treatment of CLL; the study also showed improved duratio...
Source: Johnson and Johnson - June 12, 2021 Category: Pharmaceuticals Tags: Innovation Source Type: news

Janssen Announces Results from Phase 3 MAIA Study Showing Significant Overall Survival Benefits for Treatment with DARZALEX ® (daratumumab) in Patients with Newly Diagnosed Multiple Myeloma Who are Transplant Ineligible
Raritan, N.J., June 12, 2021 – The Janssen Pharmaceutical Companies of Johnson & Johnson announced overall survival (OS) results from the Phase 3 MAIA (NCT02252172) study showing the addition of DARZALEX® (daratumumab) to lenalidomide and dexamethasone (D-Rd) resulted in a statistically significant survival benefit over lenalidomide and dexamethasone (Rd) alone in patients with newly diagnosed multiple myeloma (NDMM) who were ineligible for autologous stem cell transplant (ASCT) and were treated to progression.[1] These data were featured in the European Hematology Association (EHA) 2021 Virtual Press Briefin...
Source: Johnson and Johnson - June 12, 2021 Category: Pharmaceuticals Tags: Innovation Source Type: news

FDA approves ibrutinib plus rituximab for chronic lymphocytic leukemia
Hematology / Oncology News Burst (Source: FDA Center for Drug Evaluation and Research - What's New)
Source: FDA Center for Drug Evaluation and Research - What's New - June 11, 2021 Category: Drugs & Pharmacology Authors: FDA Source Type: news

Roche announces data at EHA2021 reinforcing efficacy of Venclexta/Venclyxto combinations in chronic lymphocytic leukaemia and acute myeloid leukaemia
Basel, 11 June 2021 - Roche (SIX: RO, ROG; OTCQX: RHHBY) today announced the latest data from three pivotal phase III studies of Venclexta ®/Venclyxto® (venetoclax) – CLL14, MURANO and VIALE-A – to be presented at the European Hematology Association Virtual Congress, June 9-17 (EHA2021). Long-term follow-up data from the CLL14 and MURANO studies support the primary analysis of Venclexta/Venclyxto in chronic lymphocytic leukaemia (CLL) and the possibility of tailoring treatment approaches based on genetic risk factors. Furthermore, the latest research shows the potential of minimal residual disease (MRD)...
Source: Roche Media News - June 11, 2021 Category: Pharmaceuticals Source Type: news

Roche announces data at EHA2021 reinforcing efficacy of Venclexta/Venclyxto combinations in chronic lymphocytic leukaemia and acute myeloid leukaemia
Basel, 11 June 2021 - Roche (SIX: RO, ROG; OTCQX: RHHBY) today announced the latest data from three pivotal phase III studies of Venclexta ®/Venclyxto® (venetoclax) – CLL14, MURANO and VIALE-A – to be presented at the European Hematology Association Virtual Congress, June 9-17 (EHA2021). Long-term follow-up data from the CLL14 and MURANO studies support the primary analysis of Venclexta/Venclyxto in chronic lymphocytic leukaemia (CLL) and the possibility of tailoring treatment approaches based on genetic risk factors. Furthermore, the latest research shows the potential of minimal residual disease (MRD)...
Source: Roche Investor Update - June 11, 2021 Category: Pharmaceuticals Source Type: news

Combination targeted therapy provides durable remission for patients with CLL
(University of Texas M. D. Anderson Cancer Center) A combination of ibrutinib and venetoclax was found to provide lasting disease remission in patients with newly diagnosed chronic lymphocytic leukemia (CLL), according to researchers at The University of Texas MD Anderson Cancer Center. Findings from the single-institution Phase II study were published today in JAMA Oncology and provide the longest follow-up data on patients treated with this drug regimen. (Source: EurekAlert! - Cancer)
Source: EurekAlert! - Cancer - June 10, 2021 Category: Cancer & Oncology Source Type: news

Janssen Highlights Commitment to Advancing Transformative Innovations in Oncology with Scientific Updates from Deep, Diverse Pipeline and Portfolio at ASCO and EHA Virtual Scientific Programs
June 1, 2021 (RARITAN, N.J.) – The Janssen Pharmaceutical Companies of Johnson & Johnson announced today that more than 30 company-sponsored studies, including six oral presentations, will be featured during the 2021 American Society of Clinical Oncology (ASCO) Annual Meeting, June 4-8. Janssen presentations will include new data and updates for both approved and investigational therapeutics that are being studied for the treatment of various solid tumors and blood cancers. Immediately following ASCO, additional data will be featured during the European Hematology Association (EHA) Virtual Congress, June 9-17. A ...
Source: Johnson and Johnson - June 1, 2021 Category: Pharmaceuticals Tags: Innovation Source Type: news

Ibrutinib for chronic lymphocytic leukaemia in Italy: high discontinuation rates for costly therapy
(Source: PharmacoEconomics and Outcomes News)
Source: PharmacoEconomics and Outcomes News - June 1, 2021 Category: Drugs & Pharmacology Source Type: news

Oncotarget: STAT3 induces the expression of GLI1 in chronic lymphocytic leukemia cells
(Impact Journals LLC) Chronic lymphocytic leukemia (CLL) is characterized by gradual accumulation of neoplastic B cells. (Source: EurekAlert! - Cancer)
Source: EurekAlert! - Cancer - May 31, 2021 Category: Cancer & Oncology Source Type: news

TG Therapeutics Announces FDA Acceptance of Biologics License Application for Ublituximab in Combination with Ukoniq (umbralisib) as a Treatment for Patients with Chronic Lymphocytic Leukemia and Small Lymphocytic Lymphoma
NEW YORK, May 25, 2021 (GLOBE NEWSWIRE) -- TG Therapeutics, Inc. (NASDAQ: TGTX), today announced that the U.S. Food and Drug Administration (FDA) has accepted the Biologics License Application (BLA) for ublituximab, the Company’s... (Source: Drugs.com - New Drug Applications)
Source: Drugs.com - New Drug Applications - May 25, 2021 Category: Drugs & Pharmacology Source Type: news

IMBRUVICA ® (ibrutinib)-Based Combination Regimen as a Fixed-Duration, First-Line Treatment for Chronic Lymphocytic Leukemia Demonstrates High Rates of Disease Control
May 19, 2021 (RARITAN, N.J.) – The Janssen Pharmaceutical Companies of Johnson & Johnson today announced new data from the fixed-duration cohort of the investigational Phase 2 CAPTIVATE study, showing that 95 percent of patients treated with combined IMBRUVICA® plus venetoclax were alive and progression-free at two years.[1] Deep remissions were seen across all subgroups, including patients with high-risk chronic lymphocytic leukemia (CLL).1 In addition, long-term data from the RESONATE-2 (PCYC-1115/1116) study will be presented, providing the longest follow-up Phase 3 data for any BTK inhibitor to date. Thes...
Source: Johnson and Johnson - May 19, 2021 Category: Pharmaceuticals Tags: Innovation Source Type: news

Efficacy of BNT162b2 mRNA COVID-19 Vaccine Lower in Patients With CLL
THURSDAY, May 6, 2021 -- The BNT162b2 mRNA COVID-19 vaccine has lower efficacy among patients with chronic lymphocytic leukemia (CLL) and induces lower neutralizing antibody responses (NAbs) in elderly patients with multiple myeloma (MM) versus... (Source: Drugs.com - Pharma News)
Source: Drugs.com - Pharma News - May 6, 2021 Category: Pharmaceuticals Source Type: news

Roche announces positive CHMP opinion for Venclyxto-based combinations in certain patients with acute myeloid leukaemia
Basel, 23 April 2021 - Roche (SIX: RO, ROG; OTCQX: RHHBY) today announced that the European Medicines Agency ’s Committee for Medicinal Products for Human Use (CHMP) has adopted a positive opinion for Venclyxto® (venetoclax) in combination with a hypomethylating agent for the treatment of adult patients with newly diagnosed acute myeloid leukaemia (AML) who are ineligible for intensive chemotherapy. Bas ed on this positive CHMP recommendation, a final decision regarding the approval of Venclyxto in certain patients with untreated AML is expected from the European Commission in the near future.“Today’s...
Source: Roche Investor Update - April 23, 2021 Category: Pharmaceuticals Source Type: news

GENUINE Improvements: Ublituximab Plus Ibrutinib for CLL GENUINE Improvements: Ublituximab Plus Ibrutinib for CLL
Chronic lymphocytic leukemia (CLL) expert Jennifer R. Brown, MD, discusses the recently published GENUINE trial and its implications for treating high-risk patients.Medscape Medical News (Source: Medscape Medical News Headlines)
Source: Medscape Medical News Headlines - April 20, 2021 Category: Consumer Health News Tags: Hematology-Oncology News Source Type: news

Science Saturday: Regenerative eyedrops tap blood for tears
Gregory Williams turned to regenerative medicine for healing after a one-two punch to his health. The 63-year-old Florida man survived?leukemia?only to develop ocular?graft-versus-host?disease, a potentially blinding complication of the bone marrow transplant that put his cancer in remission. Ocular graft-versus-host disease is a chronic debilitating condition with no cure that causes severe dry eyes. The?Regenerative [...] (Source: News from Mayo Clinic)
Source: News from Mayo Clinic - April 17, 2021 Category: Databases & Libraries Source Type: news

An antibody-drug combo to combat cancer
(Tokyo Medical and Dental University) Researchers at Tokyo Medical and Dental University (TMDU) have developed an ingenious therapeutic strategy against chronic myelomonocytic leukemia that links a cytotoxic drug payload to an antibody vector that targets the CD64 marker highly expressed by monocytes and monocytic progenitors. This selective antibody-drug conjugate spares other blood cell lineages thus avoiding the side-effects of conventional anti-cancer drugs such as anemia, infection or bleeding diatheses. Consequently, this drug-delivery tactic shows great promise against other monocyte-related diseases. (Source: EurekAlert! - Cancer)
Source: EurekAlert! - Cancer - April 16, 2021 Category: Cancer & Oncology Source Type: news

Studies suggest people with blood cancers may not be optimally protected after COVID-19 vaccination
(American Society of Hematology) Two new studies published in Blood suggest that the mRNA COVID-19 vaccine may have reduced efficacy in individuals with chronic lymphocytic leukemia (CLL) and multiple myeloma, two types of blood cancer. According to researchers, these studies could help inform the ideal time for vaccination of these populations. (Source: EurekAlert! - Infectious and Emerging Diseases)
Source: EurekAlert! - Infectious and Emerging Diseases - April 16, 2021 Category: Infectious Diseases Source Type: news

EU Panel Endorses Duvelisib for CLL and Follicular Lymphoma EU Panel Endorses Duvelisib for CLL and Follicular Lymphoma
The panel recommends EU approval for duvelisib (Copiktra) for certain patients with chronic lymphocytic leukemia (CLL) or follicular lymphoma.International Approvals (Source: Medscape Hematology-Oncology Headlines)
Source: Medscape Hematology-Oncology Headlines - March 29, 2021 Category: Cancer & Oncology Tags: Hematology-Oncology News Alert Source Type: news

TG Therapeutics Completes Rolling Submission of Biologics License Application to the U.S. Food and Drug Administration for Ublituximab in Combination with Ukoniq (umbralisib) as a Treatment for Patients with Chronic Lymphocytic Leukemia
NEW YORK, March 29, 2021 (GLOBE NEWSWIRE) -- TG Therapeutics, Inc. (NASDAQ: TGTX), today announced the completion of the rolling submission of a Biologics License Application (BLA) to the U.S. Food and Drug Administration (FDA) requesting approval... (Source: Drugs.com - New Drug Applications)
Source: Drugs.com - New Drug Applications - March 29, 2021 Category: Drugs & Pharmacology Source Type: news

Oncotarget: Hispanic Chronic myelomonocytic leukemia patients
(Impact Journals LLC) This Oncotarget study had significantly lower mutation rates in ASXL1 and SETBP1, and a higher rate of muTET2/wtASXL1 (Source: EurekAlert! - Social and Behavioral Science)
Source: EurekAlert! - Social and Behavioral Science - March 22, 2021 Category: International Medicine & Public Health Source Type: news

New BTK Inhibitor Pirtobrutinib Shows Promise in CLL New BTK Inhibitor Pirtobrutinib Shows Promise in CLL
The drug yielded promising outcomes in patients with chronic lymphocytic leukemia who discontinued BTK inhibitor treatment because of resistance or intolerance, according to results of the BRUIN trial.Medscape Medical News (Source: Medscape Medical News Headlines)
Source: Medscape Medical News Headlines - March 15, 2021 Category: Consumer Health News Tags: Hematology-Oncology News Source Type: news

What Are the Stages of Chronic Lymphocytic Leukemia?
Title: What Are the Stages of Chronic Lymphocytic Leukemia?Category: Diseases and ConditionsCreated: 2/16/2021 12:00:00 AMLast Editorial Review: 2/16/2021 12:00:00 AM (Source: MedicineNet Cancer General)
Source: MedicineNet Cancer General - February 16, 2021 Category: Cancer & Oncology Source Type: news

A potent weapon against lymphomas
(Max Delbr ü ck Center for Molecular Medicine in the Helmholtz Association) MDC researchers have developed a new approach to CAR T-cell therapy. The team has shown inNature Communications that the procedure is very effective, especially when it comes to fighting follicular lymphomas and chronic lymphocytic leukemia, the most common type of blood cancer in adults. (Source: EurekAlert! - Medicine and Health)
Source: EurekAlert! - Medicine and Health - January 11, 2021 Category: International Medicine & Public Health Source Type: news

Some English bulldogs thought to have cancer may have newly identified syndrome
(Morris Animal Foundation) Some English bulldogs diagnosed with a common cancer may instead have a newly described, non-cancerous syndrome called polyclonal B?cell lymphocytosis. The discovery was made by Morris Animal Foundation-funded researchers at Colorado State University during a study to better understand B-cell chronic lymphocytic leukemia (BCLL). The team published their findings in the Journal of Veterinary Internal Medicine. (Source: EurekAlert! - Cancer)
Source: EurekAlert! - Cancer - January 5, 2021 Category: Cancer & Oncology Source Type: news

Highlights in Chronic Lymphocytic Leukemia From ASH 2020 Highlights in Chronic Lymphocytic Leukemia From ASH 2020
Dr William Wierda from MD Anderson reviews key studies on chronic lymphocytic leukemia therapies from ASH 2020, including the phase 3 UNITY trial, next-generation BTK inhibitors, and CAR-T therapy.Medscape (Source: Medscape Today Headlines)
Source: Medscape Today Headlines - December 28, 2020 Category: Consumer Health News Tags: None ReCAP Source Type: news

On the Horizon: Asciminib, a New Drug for Treating R/R CML On the Horizon: Asciminib, a New Drug for Treating R/R CML
A first-in-class STAMP inhibitor, asciminib, shows better efficacy than bosutinib in patients with relapsed/refractory chronic myeloid leukemia in the chronic phase.Medscape Medical News (Source: Medscape Hematology-Oncology Headlines)
Source: Medscape Hematology-Oncology Headlines - December 14, 2020 Category: Cancer & Oncology Tags: Hematology-Oncology News Source Type: news

New analysis method for predicting the risks and effects of immunotherapy
(Uppsala University) In a new study, researchers at Uppsala University have been able to show differences in how Rituximab, a monoclonal antibody drug, interacts with the blood of healthy individuals compared to patients with chronic lymphocytic leukaemia. This has awakened hopes that this analysis method could pave the way for important breakthroughs in immunotherapy research and treatment. (Source: EurekAlert! - Medicine and Health)
Source: EurekAlert! - Medicine and Health - December 11, 2020 Category: International Medicine & Public Health Source Type: news

New Data Demonstrate Long-Term Benefit of IMBRUVICA ® (ibrutinib) as First-Line Treatment for High-Risk Chronic Lymphocytic Leukemia
This study highlighted the need for cytogenetic/molecular testing before CIT treatment, consistent with clinical treatment guidelines.[8],[9]Real-World Prognostic Biomarker Testing, Treatment Patterns, And Dosing Among Patients With CLL/SLL From the informCLL™ Prospective Observational Registry (Abstract #547)An oral presentation on Monday, December 7, will feature results from the informCLL™ real-world prospective observational registry assessing treatment patterns in the era of novel agents.4 Key Study Findings:· The most common index treatment was IMBRUVICA®; the majority of patients treated with ...
Source: Johnson and Johnson - December 6, 2020 Category: Pharmaceuticals Tags: Innovation Source Type: news

Roche announces new data reinforcing the long-term benefit of Venclexta/Venclyxto-based combination for people with relapsed or refractory chronic lymphocytic leukaemia
             Basel, 5 December 2020 - Roche (SIX: RO, ROG; OTCQX: RHHBY) today announced that new data from the pivotal phase III MURANO and CLL14 studies support the efficacy of fixed-duration, chemotherapy-free Venclexta ®/Venclyxto® (venetoclax)-based combinations in certain people with chronic lymphocytic leukaemia (CLL) and provide more evidence on the potential value of minimal residual disease (MRD). Data were presented at the all-virtual 62nd American Society of Hematology (ASH) Annual Meeting and Exposition on Saturday 5 December 2020.“...
Source: Roche Media News - December 5, 2020 Category: Pharmaceuticals Source Type: news

Roche announces new data reinforcing the long-term benefit of Venclexta/Venclyxto-based combination for people with relapsed or refractory chronic lymphocytic leukaemia
             Basel, 5 December 2020 - Roche (SIX: RO, ROG; OTCQX: RHHBY) today announced that new data from the pivotal phase III MURANO and CLL14 studies support the efficacy of fixed-duration, chemotherapy-free Venclexta ®/Venclyxto® (venetoclax)-based combinations in certain people with chronic lymphocytic leukaemia (CLL) and provide more evidence on the potential value of minimal residual disease (MRD). Data were presented at the all-virtual 62nd American Society of Hematology (ASH) Annual Meeting and Exposition on Saturday 5 December 2020.“...
Source: Roche Investor Update - December 5, 2020 Category: Pharmaceuticals Source Type: news

Disease-Free Survival Data from CAPTIVATE Study Demonstrate Benefit of IMBRUVICA ® (ibrutinib)-Based Regimen as Fixed Duration, First-Line Treatment for Patients with Chronic Lymphocytic Leukemia
December 5, 2020 (RARITAN, N.J.) – New data from the Phase 2 CAPTIVATE study were presented today during an oral session at the 2020 American Society of Hematology (ASH) Annual Meeting (Abstract #123). The study evaluated the efficacy and safety of IMBRUVICA® (ibrutinib) plus venetoclax in the treatment of adult patients with chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL) and showed that, after achieving undetectable minimal residual disease (uMRD) in both the blood and bone marrow with the IMBRUVICA® combination regimen, the one-year disease-free survival (DFS) of patients randomized ...
Source: Johnson and Johnson - December 5, 2020 Category: Pharmaceuticals Tags: Innovation Source Type: news

TG Therapeutics Initiates Rolling Submission of Biologics License Application to U.S. Food and Drug Administration for Ublituximab in Combination with Umbralisib as a Treatment for Patients with Chronic Lymphocytic Leukemia
NEW YORK, Dec. 01, 2020 (GLOBE NEWSWIRE) -- TG Therapeutics, Inc. (NASDAQ: TGTX) today announced that the Company has initiated a rolling submission of a Biologics License Application (BLA) to the U.S. Food and Drug... (Source: Drugs.com - New Drug Applications)
Source: Drugs.com - New Drug Applications - December 1, 2020 Category: Drugs & Pharmacology Source Type: news

Tyrosine Kinase Inhibitor Discontinuation Can Improve CML Outcomes Tyrosine Kinase Inhibitor Discontinuation Can Improve CML Outcomes
In patients with chronic myeloid leukemia (CML), discontinuing tyrosine kinase inhibitor (TKI) therapy is safe and associated with better patient-reported outcomes, a nonrandomized trial reveals.Reuters Health Information (Source: Medscape Medical News Headlines)
Source: Medscape Medical News Headlines - November 26, 2020 Category: Consumer Health News Tags: Hematology-Oncology News Source Type: news

Pigment Traits, Sun Sensitivity Tied to Risk for Blood Cancers Pigment Traits, Sun Sensitivity Tied to Risk for Blood Cancers
Risk factors for keratinocyte carcinomas were associated with the risk of developing non-Hodgkin lymphomas and chronic lymphocytic leukemia in an analysis of 92,097 women.Medscape Medical News (Source: Medscape Hematology-Oncology Headlines)
Source: Medscape Hematology-Oncology Headlines - November 25, 2020 Category: Cancer & Oncology Tags: Hematology-Oncology News Source Type: news

Are We Close to Predicting Treatment-Free Remission in CML? Are We Close to Predicting Treatment-Free Remission in CML?
Chronic myeloid leukemia expert Dr Richard Stone discusses the promise and clinical feasibility of two recently proposed predictive scores.Medscape Medical News (Source: Medscape Hematology-Oncology Headlines)
Source: Medscape Hematology-Oncology Headlines - November 20, 2020 Category: Cancer & Oncology Tags: Hematology-Oncology News Source Type: news

Renal Function Decline With TKI Use in Chronic Myeloid Leukaemia Renal Function Decline With TKI Use in Chronic Myeloid Leukaemia
Tyrosine kinase inhibitors are associated with renal function decline in patients with chronic myeloid leukaemia according to results of a 10-year follow up.Medscape News UK (Source: Medscape Medical News Headlines)
Source: Medscape Medical News Headlines - November 19, 2020 Category: Consumer Health News Tags: Hematology-Oncology News Source Type: news

Janssen Headlines American Society of Hematology Annual Meeting With More Than 35 Presentations Highlighting Deep, Diverse Oncology Pipeline and Portfolio
RARITAN, N.J., November 5, 2020 – The Janssen Pharmaceutical Companies of Johnson & Johnson announced today more than 35 company-sponsored studies, including 10 oral presentations, will be featured at the 62nd American Society of Hematology (ASH) Annual Meeting and Exposition taking place virtually December 5-8, 2020.In multiple myeloma, highlights include Phase 1b/2 results for the B-cell maturation antigen (BCMA)-targeted chimeric antigen receptor T-cell (CAR-T) therapy ciltacabtagene autoleucel (cilta-cel); new and updated data for the anti-CD38 monoclonal antibody DARZALEX® (daratumumab) and the subcutane...
Source: Johnson and Johnson - November 5, 2020 Category: Pharmaceuticals Tags: Innovation Source Type: news

What Causes Joint Pain?
DiscussionMusculoskeletal problems are common problems in pediatric practice with up to 15% of acute care visits being for this problem. Joint pain is a common concern for families but the differential diagnosis is extensive and needs thoughtful consideration. History is a key to discerning the potential diagnosis but also in guiding the physical examination and laboratory examination. Family history especially for systemic diseases should be considered. On physical examination all joints should be examined include sacroiliac and temporomandibular joints. Is this arthritis or arthralgia? Distinction between inflammatory...
Source: PediatricEducation.org - October 26, 2020 Category: Pediatrics Authors: Pediatric Education Tags: Uncategorized Source Type: news

Anticancer compounds for B cell cancer therapy targeting cellular stress response
(The Wistar Institute) Wistar and collaborators from the University of Notre Dame are developing anticancer compounds targeting a pathway of the endoplasmic reticulum (ER) stress response implicated in the development of multiple myeloma (MM), chronic lymphocytic leukemia (CLL) and lymphoma. (Source: EurekAlert! - Biology)
Source: EurekAlert! - Biology - October 13, 2020 Category: Biology Source Type: news

Meta-Analysis: Acalabrutinib Bests Other Frontline CLL Therapies Meta-Analysis: Acalabrutinib Bests Other Frontline CLL Therapies
Acalabrutinib, alone or in combination with obinutuzumab, showed favorable progression-free survival and overall survival compared with other frontline therapies for chronic lymphocytic leukemia.Medscape Medical News (Source: Medscape Hematology-Oncology Headlines)
Source: Medscape Hematology-Oncology Headlines - October 9, 2020 Category: Cancer & Oncology Tags: Hematology-Oncology News Source Type: news

The CNIO reprograms CRISPR system in mice to eliminate tumor cells without affecting healthy cells
(Centro Nacional de Investigaciones Oncol ó gicas (CNIO)) CNIO researchers destroyed Ewing's sarcoma and chronic myeloid leukaemia tumor cells by using CRISPR to cut out the fusion genes that cause them. For the first time, fusion genes have been selectively and efficiently removed using CRISPR. These genes are attracting a great deal of interest from the research community because they are unique to the tumor cell and are therefore excellent targets for the development of future drugs that only attack the tumor and are harmless for healthy cells. (Source: EurekAlert! - Cancer)
Source: EurekAlert! - Cancer - October 8, 2020 Category: Cancer & Oncology Source Type: news

Chronic Myeloid Leukemia Highlights From SOHO 2020 Chronic Myeloid Leukemia Highlights From SOHO 2020
Dose reductions for TKIs, gene signatures indicating good responders, and promising data on a new TKI are among the CML highlights from the Society of Hematologic Oncology 2020 virtual meeting.Medscape (Source: Medscape Today Headlines)
Source: Medscape Today Headlines - October 2, 2020 Category: Consumer Health News Tags: Hematology-Oncology ReCAP Source Type: news

FDA grants Fast Track designation to Calibr's 'switchable' CAR-T cell cancer therapy
(Scripps Research Institute) The US Food and Drug Administration has granted Fast Track designation to a novel 'switchable' CAR-T cell therapy developed by Calibr, a division of Scripps Research, in a move to accelerate the drug development and review process. The therapy is currently being evaluated as a treatment for B-cell malignancies, a class of blood cancers that includes non-Hodgkin's lymphoma and chronic lymphocytic leukemia. (Source: EurekAlert! - Medicine and Health)
Source: EurekAlert! - Medicine and Health - October 1, 2020 Category: International Medicine & Public Health Source Type: news

New mechanism of cell survival in chronic lymphocytic leukemia
(The Wistar Institute) Researchers at The Wistar Institute unraveled a mechanism employed by chronic lymphocytic leukemia (CLL) cells for their survival. (Source: EurekAlert! - Biology)
Source: EurekAlert! - Biology - September 30, 2020 Category: Biology Source Type: news